Neoleukin Financial Statements From 2010 to 2025

NLTXDelisted Stock  USD 0.69  0.01  1.43%   
Neoleukin Therapeutics financial statements provide useful quarterly and yearly information to potential Neoleukin Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Neoleukin Therapeutics financial statements helps investors assess Neoleukin Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Neoleukin Therapeutics' valuation are summarized below:
Neoleukin Therapeutics does not presently have any fundamental ratios for analysis.
Check Neoleukin Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neoleukin Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Neoleukin financial statements analysis is a perfect complement when working with Neoleukin Therapeutics Valuation or Volatility modules.
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Neoleukin Therapeutics Company Return On Equity Analysis

Neoleukin Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Neoleukin Therapeutics Return On Equity

    
  -0.38  
Most of Neoleukin Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neoleukin Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Neoleukin Therapeutics has a Return On Equity of -0.3788. This is 98.42% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The return on equity for all United States stocks is 22.19% higher than that of the company.

Neoleukin Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Neoleukin Therapeutics's current stock value. Our valuation model uses many indicators to compare Neoleukin Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neoleukin Therapeutics competition to find correlations between indicators driving Neoleukin Therapeutics's intrinsic value. More Info.
Neoleukin Therapeutics is regarded second in return on equity category among its peers. It is regarded fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neoleukin Therapeutics' earnings, one of the primary drivers of an investment's value.

About Neoleukin Therapeutics Financial Statements

Neoleukin Therapeutics investors use historical fundamental indicators, such as Neoleukin Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Neoleukin Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington. Neoleukin Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 79 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Other Consideration for investing in Neoleukin Stock

If you are still planning to invest in Neoleukin Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neoleukin Therapeutics' history and understand the potential risks before investing.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments